Labcorp Early Development Laboratories, Inc. – FDA 483, Jul 25, 2025

During an inspection conducted from July 21-25, 2025, by the Food and Drug Administration, Labcorp Early Development Laboratories, Inc. in Greenfield, IN, received an FDA Form 483 outlining significant observations related to their laboratory controls and quality systems. The inspection highlighted several areas of non-compliance with regulatory expectations, particularly concerning Good Manufacturing Practices. Key violations included a failure to thoroughly investigate unexplained discrepancies, such as numerous out-of-specification results and critical reagent failures, without adequately expanding investigations or implementing corrective actions. The firm's laboratory controls were found lacking, with instances of method verification using unqualified reagents and uninvestigated system suitability failures during method validation. Furthermore, deficiencies were noted in computer system controls, where raw data files were found deleted from the recycle bin, contradicting secure storage requirements. The stability program also exhibited issues, with samples stored in non-routine packaging without proper documentation and stability chamber conditions not matching qualified parameters. These observations indicate a need for Labcorp Early Development Laboratories, Inc. to implement comprehensive corrective and preventive actions. The firm is expected to address each observation by enhancing its investigation processes, strengthening laboratory control procedures for method validation and reagent qualification, ensuring robust computer system security for data integrity, and revising its stability program to align with established protocols and regulatory standards. A thorough response is required to demonstrate commitment to regulatory compliance and ensure product quality and safety.